HB 947 requires most individual health insurance policies in Montana to cover continuous glucose monitors (CGMs) and their supplies for people diagnosed with type I or type II diabetes when medically necessary, as prescribed by a healthcare provider. The bill prohibits insurers from denying coverage based on diabetes severity or insulin dependence, and bans special deductibles or limits specifically for CGMs - though standard deductibles may still apply. This affects diabetes patients covered by individual disability, health, or membership insurance plans (excluding Medicare supplements, hospital indemnity, or long-term care policies). The law aims to ensure consistent access to these critical blood sugar monitoring tools without discriminatory coverage barriers.
HB 274 sought to establish a medical respite care program in Montana for homeless individuals who are eligible for Medicaid. This program would have provided short-term housing in residential facilities with supportive medical services for those recovering from illness or injury but not requiring hospitalization. Services would have included treatment plan monitoring, medication management, immunizations, discharge planning, and transportation for medical appointments. The bill directed the Department of Public Health and Human Services to seek federal approval for the program and to report annually on its costs and the number of individuals served.
HB 807 amends state law to prohibit individuals from being required to receive certain vaccines. Specifically, it mandates that vaccines whose use is allowed under an emergency use authorization (EUA) or those still undergoing safety trials cannot be a requirement. This applies to persons, governmental entities, employers, and public accommodations, preventing them from denying services, employment, or access based on non-receipt of such vaccines. The bill integrates this new prohibition into existing law concerning discrimination based on vaccination status.
HB 888 revises the powers of local boards of health concerning isolation and quarantine orders. This bill prohibits local boards of health from requiring individuals to receive a vaccination or other medication as a condition for release from an isolation or quarantine order. It amends existing state law (Section 50-2-116, MCA) that outlines the duties of these boards. The legislation also includes an appropriation.
SB 218 establishes a private right of action, allowing minors, their legal guardians, or estates to file civil lawsuits against healthcare professionals and physicians. These lawsuits can be brought for injuries caused by specific medical interventions, including certain surgeries, hormone therapies, and puberty blockers, when provided to minors to treat gender dysphoria. Liability may arise if the injury is proximately caused by a deviation from the applicable medical standard of care. The bill sets a statute of limitations for these actions and clarifies that it does not apply to treatments for medically verifiable disorders of sex development or complications from prior medical treatments.
HB 687 revises the age range for expanded Medicaid participants who are required to engage in community engagement activities. Previously, participants aged 19 to 55 were subject to this requirement. This bill extends that upper age limit, now requiring individuals from 19 to 62 years old to participate. Affected participants must complete 80 hours per month in activities such as employment, education, work training, or community service, unless they qualify for an exemption. This change directly impacts expanded Medicaid recipients between the ages of 56 and 62.
Senate Bill 495 eliminates the Tobacco Prevention Advisory Board. The bill repeals the specific section of law that established this board. It also amends existing statute to remove the board from the list of entities funded by state special revenue accounts, which are primarily used for tobacco disease prevention programs and the Children's Health Insurance Program. The direct effect is the dissolution of the advisory board, which previously provided guidance for these programs.
HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.